On Wednesday, a new report reveals a remarkable look at internal documents from a pharmaceutical company suggests that clinical data was manipulated to make a popular epilepsy drug Neurontin look more effective than it actually was, thereby increasing possibilities for its off-label usage.

"There were a lot of primary outcomes that were shifted around between the planning of the protocol and the reporting of the study. Some primary outcomes were lost altogether. Some were brand new. Some were secondary outcomes that were upgraded to primary”, said Kay Dickersin of Johns Hopkins University in Baltimore.

Pfizer paid $ 430 million to reconcile the lawsuit over illegal endorsement of the drug, though; Dickersin acquired the entire documents while allocating it as a practiced witness against Pfizer.

Fetching the unusual case in opposition to the company for off-label marketing practices, for preventing negative study results and altering the design of its trials to construct other favorable results, the company was before now sued by lawyer Thomas Greene in preceding year.

In order to position the law suit erroneous, Pfizer arguments on the report's conclusions and states that the company never endeavored to deceive the medical community about the efficiency of the drug.

"We believe the review suffers from significant bias, insufficient data, poor methodology, and cannot pass the threshold of credible scientific research", said Pfizer.